Pre- and post-treatment biomarkers for non-small cell lung cancer treated with immune checkpoint inhibitor

被引：0
|
作者：
Murata, D. [1 ]
Azuma, K. [1 ]
Nishii, Y. [1 ]
Tokito, T. [1 ]
Hoshino, T. [1 ]
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Kurume Univ Hosp, Kurume, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO10-1
引用
收藏
页码：S1333 / S1333
页数：1
相关论文
共 50 条
  • [31] A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer
    Fukui, T.
    Nakahara, Y.
    Otani, S.
    Katagiri, M.
    Mitsufuji, H.
    Kubota, M.
    Hiyoshi, Y.
    Ishihara, M.
    Kasajima, M.
    Igawa, S.
    Sasaki, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 135 - 135
  • [32] Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
    Walsh, Robert J.
    Soo, Ross A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [33] Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors
    Murata, Daiki
    Azuma, Koichi
    Matsuo, Norikazu
    Murotani, Kenta
    Matama, Goushi
    Kawahara, Akihiko
    Sasada, Tetsuro
    Tokito, Takaaki
    Hoshino, Tomoaki
    CANCER MEDICINE, 2023, 12 (19): : 19471 - 19479
  • [34] Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
    Pradhan, Monika
    Chocry, Mathieu
    Gibbons, Don L.
    Sepesi, Boris
    Cascone, Tina
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 590 - 606
  • [35] Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy
    Mock, J.
    Wynter, E.
    Young, P.
    Sytov, A.
    Elghawy, O.
    Gentzler, R.
    Novicoff, W.
    Martin, L.
    Hall, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S20 - S21
  • [36] Prognostic impact and predictive biomarkers of immune checkpoint inhibitor-induced interstitial lung disease for non-small cell lung cancer
    Murata, Daiki
    Azuma, Koichi
    Matsuo, Norikazu
    Tokito, Takaaki
    Hoshino, Tomoaki
    ANNALS OF ONCOLOGY, 2023, 34 : S1430 - S1430
  • [37] PRE- EXISTING INTERSTITIAL LUNG ABNORMALITIES ARE RISK FACTORS FOR IMMUNE CHECKPOINT INHIBITORINDUCED INTERSTITIAL LUNG DISEASE IN NON-SMALL CELL LUNG CANCER
    Masuda, Takeshi
    Nakanishi, Yu
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Hattori, Noboru
    RESPIROLOGY, 2019, 24 : 248 - 249
  • [38] The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
    Corke, Lucy K.
    Li, Janice J. N.
    Leighl, Natasha B.
    Eng, Lawson
    CURRENT ONCOLOGY, 2022, 29 (09) : 6260 - 6276
  • [40] Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients
    Kubo, T.
    Watanabe, H.
    Ninomiya, K.
    Kudo, K.
    Minami, D.
    Murakami, E.
    Ochi, N.
    Ninomiya, T.
    Harada, D.
    Yasugi, M.
    Ichihara, E.
    Ohashi, K.
    Fujiwara, K.
    Hotta, K.
    Tabata, M.
    Maeda, Y.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2018, 29
12345